https://www.prognyx.com/blog/merck-licenses-preclinical-kras-g12d-on-inhibitor-spr2015-from-scibrunchPrognyxen2026-09-30Merck licenses preclinical KRAS G12D(ON) inhibitor SPR2015 from SciBrunch https://www.prognyx.com/blog/astrazeneca-takes-2b-summit-stake-pairs-its-claudin-18-2-adc-with-ivonescimabPrognyxen2026-09-29AstraZeneca takes $2B Summit stake, pairs its Claudin 18.2 ADC with ivonescimab